Implantable cardiac defibrillator leads dysfunction after LVAD implantation

Pacing Clin Electrophysiol. 2020 Nov;43(11):1309-1317. doi: 10.1111/pace.14004. Epub 2020 Jul 24.

Abstract

Background: Implantable cardioverter-defibrillator (ICD) lead dysfunction has been reported after left ventricular assist device (LVAD) implantation in limited single-center studies. We aimed at describing and characterizing the incidence of ICD lead parameters dysfunction after LVAD implantation.

Methods: Among the 652 patients enrolled in the ASSIST-ICD study, only patients with an ICD prior to LVAD were included (n = 401). ICD lead parameters dysfunction following LVAD implantation is defined as follows: (a) >50% decrease in sensing threshold, (b) pacing lead impedance increase/decrease by >100Ω, and (c) >50% increase in pacing threshold.

Results: One hundred twenty-two patients with an ICD prior to LVAD had available ICD interrogation reports prior and after LVAD. A total of 67 (55%) patients exhibited at least one significant lead dysfunction: 17 (15%) exhibited >50% decrease in right ventricular (RV) sensing, 51 (42%) had >100 Ω increase/decrease in RV pacing impedance, and 24 (20%) experienced >50% increase in RV pacing threshold. A total of 52 patients experienced ventricular arrhythmia during follow-up and all were successfully detected and treated by the device. All lead dysfunction could be managed conservatively.

Conclusion: More than 50% of LVAD-recipients may experience >1 significant change in lead parameters but none had severe clinical consequences.

Keywords: implantable cardioverter defibrillator; lead parameters dysfunction; left ventricular assist device.

Publication types

  • Multicenter Study
  • Observational Study

MeSH terms

  • Aged
  • Defibrillators, Implantable / adverse effects*
  • Electrodes, Implanted / adverse effects*
  • France
  • Heart-Assist Devices*
  • Humans
  • Male
  • Middle Aged
  • Prosthesis Failure